TSAT as a diagnostic marker for Iron Deficiency in oncological patients – prevalence of iron deficiency and effectiveness as well as tolerability of treatment with ferric carboxymaltose (FCM): a two-step non-interventional study - TIDO-NIS

Vifor Pharma Deutschland GmbH0 个研究点目标入组 405 人开始时间: 2019年10月17日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•- Age over 18 years
•- Proven malignant solid or hematologic tumor disease
•- first contact in an oncological doctor's office
•- Written consent of the patient to participate in the study incl. Data usage in compliance with the Data Protection Act (BDSG)
•- Newly initiated systemic treatment with antitumour therapy and expected treatment duration of more than 12 weeks
•- administration of systemic antitumor therapy in the participating physician practice
•- Life expectancy of more than 12 weeks
•- Regulation of iron carboxymaltose before the beginning of the treatment phase by the attending oncologist, regardless of participation in the study and taking into account local medical practice and local authorization.
•- Patients' willingness to fill in quality of life questionnaires and well-being information over a 12-week period

•- Known contraindication to the administration of iron carboxymaltose according to the latest product information
•- Detection of myelodysplastic syndrome, myeloproliferative neoplasia or acute melodic leukemia

发起方